Based on these results, olaparib in combination with bevacizumab was approved for patients with high-grade carcinomas who have responded to platinum-containing chemotherapy or who have “no evidence of disease” and have either a BRCA1/2 mutation or an HRD, exclusively. Here, BRCA1 is linked to carcinoma.